Articles
-
2 months ago |
onlinelibrary.wiley.com | Divya Shan |Marisa Riley |David M. Milgraum
1 Introduction Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor alpha, has transformed the management of moderate-to-severe atopic dermatitis. While it offers substantial relief for many patients, emerging reports have identified an adverse effect not highlighted in initial clinical trials: erythematous eruptions on the head and neck [1].
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1
- Tweets
- 536
- DMs Open
- No
RT @vinhlegacy: @Vinstar66 only thing i can see is Bob Marley
RT @lisa_liberal: Best sign I’ve seen so far. https://t.co/visXJqnDcB
RT @shitpostverdade: https://t.co/V1SjhGO6C3